Paratek Pharmaceuticals Inc (NASDAQ:PRTK)’s share price was down 7.3% during mid-day trading on Tuesday . The stock traded as low as $6.79 and last traded at $6.85. Approximately 720,457 shares changed hands during mid-day trading, an increase of 11% from the average daily volume of 648,693 shares. The stock had previously closed at $7.39.

Several equities analysts recently issued reports on PRTK shares. ValuEngine upgraded shares of Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 2nd. Bank of America started coverage on shares of Paratek Pharmaceuticals in a research note on Monday, August 27th. They issued a “neutral” rating and a $13.00 target price for the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $50.00 target price on shares of Paratek Pharmaceuticals in a research note on Thursday, August 2nd. Wedbush set a $20.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, Guggenheim set a $26.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 3rd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $30.29.

The company has a current ratio of 11.39, a quick ratio of 11.39 and a debt-to-equity ratio of 3.97. The stock has a market capitalization of $239.45 million, a price-to-earnings ratio of -2.08 and a beta of 0.74.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.16). The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $5.89 million. Paratek Pharmaceuticals had a negative return on equity of 132.55% and a negative net margin of 2,155.03%. On average, research analysts forecast that Paratek Pharmaceuticals Inc will post -3.24 EPS for the current fiscal year.

In other Paratek Pharmaceuticals news, VP Adam Woodrow sold 8,750 shares of the company’s stock in a transaction on Wednesday, October 3rd. The shares were sold at an average price of $9.82, for a total transaction of $85,925.00. Following the completion of the transaction, the vice president now directly owns 112,917 shares in the company, valued at $1,108,844.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Evan Loh sold 8,861 shares of the company’s stock in a transaction on Wednesday, October 3rd. The stock was sold at an average price of $9.82, for a total transaction of $87,015.02. Following the transaction, the chief operating officer now owns 235,286 shares of the company’s stock, valued at $2,310,508.52. The disclosure for this sale can be found here. Insiders have sold 58,446 shares of company stock valued at $559,369 over the last 90 days. 6.20% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of PRTK. Wells Fargo & Company MN grew its holdings in shares of Paratek Pharmaceuticals by 42.0% during the first quarter. Wells Fargo & Company MN now owns 27,498 shares of the specialty pharmaceutical company’s stock worth $357,000 after buying an additional 8,140 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Paratek Pharmaceuticals by 6.6% during the first quarter. BlackRock Inc. now owns 2,028,845 shares of the specialty pharmaceutical company’s stock worth $26,374,000 after buying an additional 125,194 shares in the last quarter. LPL Financial LLC grew its holdings in shares of Paratek Pharmaceuticals by 14.2% during the first quarter. LPL Financial LLC now owns 50,925 shares of the specialty pharmaceutical company’s stock worth $662,000 after buying an additional 6,350 shares in the last quarter. Trellus Management Company LLC grew its holdings in shares of Paratek Pharmaceuticals by 11.5% during the second quarter. Trellus Management Company LLC now owns 100,000 shares of the specialty pharmaceutical company’s stock worth $1,020,000 after buying an additional 10,300 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Paratek Pharmaceuticals during the second quarter worth $627,000. Institutional investors own 76.93% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Paratek Pharmaceuticals (PRTK) Stock Price Down 7.3%” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2018/11/13/paratek-pharmaceuticals-prtk-stock-price-down-7-3.html.

Paratek Pharmaceuticals Company Profile (NASDAQ:PRTK)

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Further Reading: What is Considered a Good Return on Equity (ROE)?

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.